Vedat Tiyerili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vedat Tiyerili has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Georg Nickenig
Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany
5 shared publications- Georg Nickenig
Department of Cardiology, Heart Center Bonn, University Hospital Bonn, Bonn, Germany
4 shared publications - Marc Ulrich Becher
Department of Internal Medicine and Cardiology University Hospital Bonn Bonn Nordrhein‐Westfalen Germany
3 shared publications Bakary Camara
Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
2 shared publicationsChristoph Hammerstingl
Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany
2 shared publicationsJan W. Schrickel
Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
2 shared publications
Latest Publications
- Open Access
- 12 July 2022
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 41, 101081
3D-speckle-tracking echocardiography correlates with cardiovascular magnetic resonance imaging diagnosis of acute myocarditis – An observational study
- 12 July 2022
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 41, 101081
Open Access3D-speckle-tracking echocardiography correlates with cardiovascular magnetic resonance imaging diagnosis of acute myocarditis – An observational study
- 1 August 2016
- Published by Elsevier in Atherosclerosis
- Vol. 251, 430-437
Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice
- 1 August 2016
- Published by Elsevier in Atherosclerosis
- Vol. 251, 430-437
Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice
- 1 February 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 204, 29-36
Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice
- 1 February 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 204, 29-36
Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice
- 22 July 2015
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 104 (12) , 1106-1108
Catch of the day: interventional device retrieval after late embolization of an Amplatzer cardiac plug left atrial appendage occluder
Transcatheter left atrial appendage (LAA) closure has proven to be an effective method to reduce the risk of thromboembolic events in patients who have nonvalvular atrial fibrillation (AF) that is unsuitable for chronic oral anticoagulation. In this case report, we describe the rare case of a late LAA occluder (28-mm Amplatzer cardiac plug) embolization, which was treated uneventfully with interventional device capture. Special interventional and device specific characteristics must be taken into account when planning such a complex procedure as descirbed in our case.
- 22 July 2015
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 104 (12) , 1106-1108
Catch of the day: interventional device retrieval after late embolization of an Amplatzer cardiac plug left atrial appendage occluder
Transcatheter left atrial appendage (LAA) closure has proven to be an effective method to reduce the risk of thromboembolic events in patients who have nonvalvular atrial fibrillation (AF) that is unsuitable for chronic oral anticoagulation. In this case report, we describe the rare case of a late LAA occluder (28-mm Amplatzer cardiac plug) embolization, which was treated uneventfully with interventional device capture. Special interventional and device specific characteristics must be taken into account when planning such a complex procedure as descirbed in our case.
- 31 May 2013
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 14 (11) , 1116
A 39-year-old woman with silent endocarditis of a caged-ball mitral valve
A 39-year-old woman with a caged-ball mechanical mitral valve prosthesis (Star Edward, implanted 1994 in India after mitral valve endocarditis) was admitted to our hospital with suspected infective endocarditis due to persistent fever >38°C and Staphylococcus aureus in blood culture. Owing to a …
- 31 May 2013
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 14 (11) , 1116
A 39-year-old woman with silent endocarditis of a caged-ball mitral valve
A 39-year-old woman with a caged-ball mechanical mitral valve prosthesis (Star Edward, implanted 1994 in India after mitral valve endocarditis) was admitted to our hospital with suspected infective endocarditis due to persistent fever >38°C and Staphylococcus aureus in blood culture. Owing to a …
- Open Access
- 1 January 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 30
AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ
Peroxisome-proliferator–activated-receptor-γ (PPARγ) acts as a transcriptional regulator of multiple genes involved in glucose and lipid metabolism. In vitro studies showed that activated PPARγ suppresses AT1R-gene expression and vice versa. However, it has not yet been determined in vivo, whether AT1R-PPARγ-interactions play a relevant role in the pathogenesis of diabetic complications and specifically in accelerated atherosclerosis. ApoE−/− and ApoE−/−/AT1R−/−-mice were rendered diabetic by intraperitoneal injections of streptozotocin. Diabetic and non-diabetic ApoE−/−-mice were further randomized to receive the AT1R antagonist telmisartan, the selective PPARγ antagonist GW9662, telmisartan and GW9662 or vehicle for 18 weeks. Diabetic and non-diabetic ApoE−/−/AT1R−/−-mice were randomized to receive either GW9662 or vehicle. GW9662 treatment in diabetic ApoE−/− and diabetic ApoE−/−/AT1−/−-mice resulted in the highest elevation of fasting blood glucose levels, whereas telmisartan treatment and AT1 deficiency in ApoE−/−-mice showed the lowest fasting blood glucose levels. Diabetic ApoE−/−-mice displayed severe impairment of endothelial function, enhanced oxidative stress and increased atherosclerotic lesion formation. ApoE−/−/AT1R−/− and telmisartan-treated ApoE−/−-mice showed a significantly better endothelial function, decreased oxidative stress and reduced atherosclerotic lesion formation. Treatment of diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice with the selective PPARγ antagonist GW9662 omitted the atheroprotective effects of AT1R deficiency or AT1 antagonism. Genetic disruption or pharmacological inhibition of the AT1R attenuates atherosclerosis and improves endothelial function in diabetic ApoE−/−-mice via the PPARγ pathway.
- 1 January 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 30
Open AccessAT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ
Peroxisome-proliferator–activated-receptor-γ (PPARγ) acts as a transcriptional regulator of multiple genes involved in glucose and lipid metabolism. In vitro studies showed that activated PPARγ suppresses AT1R-gene expression and vice versa. However, it has not yet been determined in vivo, whether AT1R-PPARγ-interactions play a relevant role in the pathogenesis of diabetic complications and specifically in accelerated atherosclerosis. ApoE−/− and ApoE−/−/AT1R−/−-mice were rendered diabetic by intraperitoneal injections of streptozotocin. Diabetic and non-diabetic ApoE−/−-mice were further randomized to receive the AT1R antagonist telmisartan, the selective PPARγ antagonist GW9662, telmisartan and GW9662 or vehicle for 18 weeks. Diabetic and non-diabetic ApoE−/−/AT1R−/−-mice were randomized to receive either GW9662 or vehicle. GW9662 treatment in diabetic ApoE−/− and diabetic ApoE−/−/AT1−/−-mice resulted in the highest elevation of fasting blood glucose levels, whereas telmisartan treatment and AT1 deficiency in ApoE−/−-mice showed the lowest fasting blood glucose levels. Diabetic ApoE−/−-mice displayed severe impairment of endothelial function, enhanced oxidative stress and increased atherosclerotic lesion formation. ApoE−/−/AT1R−/− and telmisartan-treated ApoE−/−-mice showed a significantly better endothelial function, decreased oxidative stress and reduced atherosclerotic lesion formation. Treatment of diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice with the selective PPARγ antagonist GW9662 omitted the atheroprotective effects of AT1R deficiency or AT1 antagonism. Genetic disruption or pharmacological inhibition of the AT1R attenuates atherosclerosis and improves endothelial function in diabetic ApoE−/−-mice via the PPARγ pathway.
- Open Access
- 13 August 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (4) , R152
Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction
Introduction: Cardiogenic shock (CS) remains the leading cause of death in patients hospitalized for myocardial infarction (MI). Systemic inflammation with inappropriate vasodilatation is observed in many patients with CS and may contribute to an excess mortality rate. The purpose of this study was to determine the predictive role of serial measurements of Nt-proBNP, interleukin-6 (IL-6), and procalcitonin (PCT) for 30-day mortality in patients with CS due to MI. Methods: The present study is a prospective single-center study including 87 patients with MI complicated by CS treated with acute revascularization and intraaortic balloon counterpulsation (IABP) support. Predictive values of plasma levels at admission (T0), after 24 hours (T1), and after 72 hours (T2) were examined according to 30-day mortality. Results: Significant differences between survivors (n = 59) and nonsurvivors (n = 28) were seen for Nt-proBNP at T0, for IL-6 at T0 and T1, and for PCT at T1 and T2. According to ROC analyses, the highest accuracy predicting 30-day mortality was seen at T0 for IL-6, at T1 for PCT, and at T2 for PCT. In univariate analysis, significant values were found for Nt-proBNP at T1, and for IL-6 and PCT at all points in time. Within the multivariate analysis, age, creatinine, and IL-6 were significant determinants of 30-day mortality, in which IL-6 showed the highest level of significance. Conclusions: In patients with MI complicated by CS, IL-6 represented a reliable independent early prognostic marker of 30-day mortality. PCT revealed a significant value at later points in time, whereas Nt-proBNP seemed to be of lower relevance.
- 13 August 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (4) , R152
Open AccessInterleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction
Introduction: Cardiogenic shock (CS) remains the leading cause of death in patients hospitalized for myocardial infarction (MI). Systemic inflammation with inappropriate vasodilatation is observed in many patients with CS and may contribute to an excess mortality rate. The purpose of this study was to determine the predictive role of serial measurements of Nt-proBNP, interleukin-6 (IL-6), and procalcitonin (PCT) for 30-day mortality in patients with CS due to MI. Methods: The present study is a prospective single-center study including 87 patients with MI complicated by CS treated with acute revascularization and intraaortic balloon counterpulsation (IABP) support. Predictive values of plasma levels at admission (T0), after 24 hours (T1), and after 72 hours (T2) were examined according to 30-day mortality. Results: Significant differences between survivors (n = 59) and nonsurvivors (n = 28) were seen for Nt-proBNP at T0, for IL-6 at T0 and T1, and for PCT at T1 and T2. According to ROC analyses, the highest accuracy predicting 30-day mortality was seen at T0 for IL-6, at T1 for PCT, and at T2 for PCT. In univariate analysis, significant values were found for Nt-proBNP at T1, and for IL-6 and PCT at all points in time. Within the multivariate analysis, age, creatinine, and IL-6 were significant determinants of 30-day mortality, in which IL-6 showed the highest level of significance. Conclusions: In patients with MI complicated by CS, IL-6 represented a reliable independent early prognostic marker of 30-day mortality. PCT revealed a significant value at later points in time, whereas Nt-proBNP seemed to be of lower relevance.
- Open Access
- 5 March 2011
- Published by Springer Nature in EPMA Journal
- Vol. 2 (1) , 119-130
Personalized cardiac regeneration by stem cells–Hype or hope?
Cardiac diseases are the leading cause of death and reach epidemic proportions with aging. Advanced heart disease results from an abrupt or progressive loss of contractile cardiomyocytes. Following percutaneous coronary intervention and revascularization regenerative medicine aims at effectively repair damaged tissue and replacement of lost cardiomyocytes. However, mixed results were obtained from trials using bone marrow-derived stem cells. Benefits were rather attributed to paracrine effects leading to inhibition or reverse of negative remodeling processes than to regeneration of viable cardiomyocytes. Thus the aim of regenerative medicine, in particular stem cell research, to generate viable cardiac muscle has so far not been achieved in humans, reflecting our incomplete understanding of underlying biological mechanisms. Moreover, there is growing evidence that substantial person-to-person differences in the outcome of stem cell therapy exists. We here review our present knowledge in evolving stem cell based cardiovascular medicine and highlight personalized aspects of stem cell interventions.
- 5 March 2011
- Published by Springer Nature in EPMA Journal
- Vol. 2 (1) , 119-130
Open AccessPersonalized cardiac regeneration by stem cells–Hype or hope?
Cardiac diseases are the leading cause of death and reach epidemic proportions with aging. Advanced heart disease results from an abrupt or progressive loss of contractile cardiomyocytes. Following percutaneous coronary intervention and revascularization regenerative medicine aims at effectively repair damaged tissue and replacement of lost cardiomyocytes. However, mixed results were obtained from trials using bone marrow-derived stem cells. Benefits were rather attributed to paracrine effects leading to inhibition or reverse of negative remodeling processes than to regeneration of viable cardiomyocytes. Thus the aim of regenerative medicine, in particular stem cell research, to generate viable cardiac muscle has so far not been achieved in humans, reflecting our incomplete understanding of underlying biological mechanisms. Moreover, there is growing evidence that substantial person-to-person differences in the outcome of stem cell therapy exists. We here review our present knowledge in evolving stem cell based cardiovascular medicine and highlight personalized aspects of stem cell interventions.
- 26 November 2010
- Published by Springer Nature in Current Hypertension Reports
- Vol. 13 (1) , 86-92
Endothelial Damage and Regeneration: The Role of the Renin-Angiotensin-Aldosterone System
The renin-angiotensin-aldosterone system (RAAS) is part of the blood pressure regulating system. Its main effector peptide is angiotensin II (Ang II). Although it may induce hypertension, the proinflammatory, profibrotic, and prothrombotic effects are mainly mediated by effects of Ang II on the cellular and molecular level that are independent of blood pressure. Therefore, pharmacotherapeutic intervention within the RAAS is an important treatment modality for patients suffering from cardiovascular diseases, even those who are not hypertensive. In addition to the blood pressure lowering and vasculoprotective (pleiotropic) effects of angiotensin II type 1 (AT1) receptor blockers (ARBs), and angiotensin-converting enzyme (ACE) inhibitors, regenerative progenitor cell therapy emerges as an auxiliary therapy to improve regeneration of the vascular endothelium. This review focuses on the growing knowledge about regenerating vascular cells, their response to RAAS effectors, and RAAS-modulating pharmacotherapy in the context of endothelial cell damage and regeneration.
- 26 November 2010
- Published by Springer Nature in Current Hypertension Reports
- Vol. 13 (1) , 86-92
Endothelial Damage and Regeneration: The Role of the Renin-Angiotensin-Aldosterone System
The renin-angiotensin-aldosterone system (RAAS) is part of the blood pressure regulating system. Its main effector peptide is angiotensin II (Ang II). Although it may induce hypertension, the proinflammatory, profibrotic, and prothrombotic effects are mainly mediated by effects of Ang II on the cellular and molecular level that are independent of blood pressure. Therefore, pharmacotherapeutic intervention within the RAAS is an important treatment modality for patients suffering from cardiovascular diseases, even those who are not hypertensive. In addition to the blood pressure lowering and vasculoprotective (pleiotropic) effects of angiotensin II type 1 (AT1) receptor blockers (ARBs), and angiotensin-converting enzyme (ACE) inhibitors, regenerative progenitor cell therapy emerges as an auxiliary therapy to improve regeneration of the vascular endothelium. This review focuses on the growing knowledge about regenerating vascular cells, their response to RAAS effectors, and RAAS-modulating pharmacotherapy in the context of endothelial cell damage and regeneration.
- 2 November 2010
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 135 (45) , 2235-2238
Unklare akute respiratorische Insuffizienz bei einer 64-jährigen Patientin nach Koronarintervention
Anamnese und klinischer Befund: Aufgrund eines retroperitonealen Hämatoms in Folge einer Herzkatheteruntersuchung wurden einer 64-jährigen Patientin zwei Erythrozytenkonzentrate transfundiert. Innerhalb der ersten Stunde nach Transfusion entwickelten sich akute Dyspnoe, Angstgefühle und Schüttelfrost. Untersuchungen: In der daraufhin erfolgten Computertomographie des Thorax präsentierte sich ein neu aufgetretenes bilaterales, basal betontes Lungenödem. Eine Lungenembolie lag nicht vor. Auch eine kardiale Ursache im Sinne eines kardiogenen Schocks konnte mittels Echokardiographie und nicht-invasiven Methoden ausgeschlossen werden. Hinweise auf eine Volumenüberladung (transfusion associated circulatory overload [TACO]) durch Gabe der Erythrozytenkonzentrate ergaben sich ebenfalls nicht. Ebenso konnte bei unveränderter Größe des retroperitonealen Hämatoms ein hämorrhagischer Schock ausgeschlossen werden. Das klinische Bild machte demnach ein transfusionsassoziiertes akutes Lungenversagen (TRALI) als Ursache für das Lungenödem wahrscheinlich. Therapie und Verlauf: Die Patientin musste intubiert werden und benötigte eine Katecholaminmedikation. Das Weaning nach Stabilisierung war komplikationslos, so dass die Patientin nach wenigen Tagen extubiert werden konnte. Das anschließende Röntgen des Thorax ergab keine pulmonalen Residuen. Zwei Wochen später wurde die Patientin in eine Rehabilitationsklinik verlegt. Folgerung: TRALI ist eine lebensbedrohliche und oft übersehene Komplikation nach Transfusion plasmahaltiger Blutprodukte. Die Diagnose wird anhand der klinischen Symptomatik in Verbindung mit radiologischen Zeichen eines Lungenödems gestellt und basiert auf den Kriterien des europäischen Hämovigilanznetzwerkes (EHN-Kriterien). Bei Verdacht auf TRALI ist das beteiligte Transfusionszentrum zu informieren. Die Durchführung einer Kreuzprobe von Spenderplasma mit Granulozyten des Empfängers ermöglicht in der überwiegenden Zahl der Fälle einen Nachweis verursachender Antikörper. Bei 17 % der Fälle sind diese nicht nachweisbar. History and admission findings: Due to a retroperitoneal hematoma after cardiac catheterization a 64 year-old woman received two concentrates of red blood cells. Within two hours after transfusion the patient developed acute dyspnoea, anxiety and shivering. Investigations: Computertomography (CT) of the chest revealed a new bilateral, basally accented pulmonary edema. Pulmonary embolism was ruled out. A cardiac cause in terms of cardiogenic shock had been excluded by echocardiography and other non-invasive measurements. Moreover, no circulatory overload (transfusion-associated circulatory overload [TACO]) after transfusion was presented and the stable size of the retroperitoneal hematoma excluded haemorrhagic shock. Hence, the clinical pattern pointed towards a transfusion-related acute lung injury (TRALI). Treatment and course:The patient was intubated and a catecholamine medication was initiated. The weaning process proceeded without complications and the patient was extubated after several days. In the following chest x-ray no pulmonary residuals were left. After two weeks the patient was transferred to a rehabilitation unit. Conclusion: TRALI is a life-threatening and an often unconsidered complication after transfusion of plasma containing blood products. According to the criteria of the european haemovigilance networks (EHN-criteria), TRALI is diagnosed by clinical and radiological parameters. In case of suspicious TRALI the involved transfusion center has to be informed. By a crossmatch between donor plasma and recipient granulocytes the causal antibodies are detected in most cases. In 17 % of cases no antibodies are detected.
- 2 November 2010
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 135 (45) , 2235-2238
Unklare akute respiratorische Insuffizienz bei einer 64-jährigen Patientin nach Koronarintervention
Anamnese und klinischer Befund: Aufgrund eines retroperitonealen Hämatoms in Folge einer Herzkatheteruntersuchung wurden einer 64-jährigen Patientin zwei Erythrozytenkonzentrate transfundiert. Innerhalb der ersten Stunde nach Transfusion entwickelten sich akute Dyspnoe, Angstgefühle und Schüttelfrost. Untersuchungen: In der daraufhin erfolgten Computertomographie des Thorax präsentierte sich ein neu aufgetretenes bilaterales, basal betontes Lungenödem. Eine Lungenembolie lag nicht vor. Auch eine kardiale Ursache im Sinne eines kardiogenen Schocks konnte mittels Echokardiographie und nicht-invasiven Methoden ausgeschlossen werden. Hinweise auf eine Volumenüberladung (transfusion associated circulatory overload [TACO]) durch Gabe der Erythrozytenkonzentrate ergaben sich ebenfalls nicht. Ebenso konnte bei unveränderter Größe des retroperitonealen Hämatoms ein hämorrhagischer Schock ausgeschlossen werden. Das klinische Bild machte demnach ein transfusionsassoziiertes akutes Lungenversagen (TRALI) als Ursache für das Lungenödem wahrscheinlich. Therapie und Verlauf: Die Patientin musste intubiert werden und benötigte eine Katecholaminmedikation. Das Weaning nach Stabilisierung war komplikationslos, so dass die Patientin nach wenigen Tagen extubiert werden konnte. Das anschließende Röntgen des Thorax ergab keine pulmonalen Residuen. Zwei Wochen später wurde die Patientin in eine Rehabilitationsklinik verlegt. Folgerung: TRALI ist eine lebensbedrohliche und oft übersehene Komplikation nach Transfusion plasmahaltiger Blutprodukte. Die Diagnose wird anhand der klinischen Symptomatik in Verbindung mit radiologischen Zeichen eines Lungenödems gestellt und basiert auf den Kriterien des europäischen Hämovigilanznetzwerkes (EHN-Kriterien). Bei Verdacht auf TRALI ist das beteiligte Transfusionszentrum zu informieren. Die Durchführung einer Kreuzprobe von Spenderplasma mit Granulozyten des Empfängers ermöglicht in der überwiegenden Zahl der Fälle einen Nachweis verursachender Antikörper. Bei 17 % der Fälle sind diese nicht nachweisbar. History and admission findings: Due to a retroperitoneal hematoma after cardiac catheterization a 64 year-old woman received two concentrates of red blood cells. Within two hours after transfusion the patient developed acute dyspnoea, anxiety and shivering. Investigations: Computertomography (CT) of the chest revealed a new bilateral, basally accented pulmonary edema. Pulmonary embolism was ruled out. A cardiac cause in terms of cardiogenic shock had been excluded by echocardiography and other non-invasive measurements. Moreover, no circulatory overload (transfusion-associated circulatory overload [TACO]) after transfusion was presented and the stable size of the retroperitoneal hematoma excluded haemorrhagic shock. Hence, the clinical pattern pointed towards a transfusion-related acute lung injury (TRALI). Treatment and course:The patient was intubated and a catecholamine medication was initiated. The weaning process proceeded without complications and the patient was extubated after several days. In the following chest x-ray no pulmonary residuals were left. After two weeks the patient was transferred to a rehabilitation unit. Conclusion: TRALI is a life-threatening and an often unconsidered complication after transfusion of plasma containing blood products. According to the criteria of the european haemovigilance networks (EHN-criteria), TRALI is diagnosed by clinical and radiological parameters. In case of suspicious TRALI the involved transfusion center has to be informed. By a crossmatch between donor plasma and recipient granulocytes the causal antibodies are detected in most cases. In 17 % of cases no antibodies are detected.